CCG Wealth Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

CCG Wealth Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400	Closed	-$2K	–	117
2022 Q2	$2K	Hold	400	–	–	﹤0.01%	110
2022 Q1	$4K	Hold	400	–	–	﹤0.01%	123
2021 Q4	$6K	Hold	400	–	–	﹤0.01%	96
2021 Q3	$12K	Sell	400 -19	-5%	-$536	0.01%	107
2021 Q2	$14K	Hold	419	–	–	0.01%	88
2021 Q1	$17K	Hold	419	–	–	0.02%	78
2020 Q4	$25K	Buy	+419	New	+$45.4K	0.03%	83

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CCG Wealth Management's NBRV Position: Q3 2022 in Review

CCG Wealth Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2022, closing a stake of 400 shares — an estimated $2K sold.

CCG Wealth Management first reported a position in NBRV in Q4 2020 and held it in 7 quarters. The position peaked at $25K in Q4 2020. 13 funds tracked by Wall St. Rank hold NBRV as of Q3 2022.

CCG Wealth Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2022 after selling out during the quarter.
CCG Wealth Management sold 400 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2022, an estimated $2K.
CCG Wealth Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2020 and held it in 7 quarters.
CCG Wealth Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $25K in Q4 2020.
13 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2022.

Based on CCG Wealth Management's 13F filing for Q3 2022, filed 18 Oct 2022.